Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Petrella, TM; Robert, C; Richtig, E; Miller, WH; Masucci, GV; Walpole, E; Lebbe, C; Steven, N; Middleton, MR; Hille, D; Zhou, W; Ibrahim, N; Cebon, J.
Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
Eur J Cancer. 2017; 86(5):115-124
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Richtig Erika
Gendermonitor:
Altmetrics:

Abstract:
Report results of patient-reported health-related quality of life (HRQoL) and symptoms from phase III KEYNOTE-006 study of pembrolizumab versus ipilimumab in patients with ipilimumab-naive advanced melanoma. Patients received pembrolizumab 10 mg/kg every 2 (Q2W) or every 3 weeks (Q3W) for up to 2 years, or four cycles of ipilimumab 3 mg/kg Q3W. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) was administered at baseline and throughout the study. Patient-reported outcome (PRO) analyses were pre-specified exploratory endpoints; the primary PRO assessment was the score change from baseline to week 12 in EORTC QLQ-C30 global health status (GHS)/HRQoL score between the arms using constrained longitudinal data analysis. The PRO analysis population included 776 patients: pembrolizumab Q2W (n = 270); pembrolizumab Q3W (n = 266); ipilimumab (n = 240). Baseline GHS was similar across arms. QLQ-C30 compliance rates at week 12 were 87% (n = 214), 97% (n = 226), and 96% (n = 178), for the pembrolizumab Q2W, pembrolizumab Q3W, and ipilimumab arms, respectively. From baseline to week 12, GHS/HRQoL scores were better maintained with pembrolizumab than with ipilimumab (decrease of -1.9 and -2.5 for pembrolizumab versus -10.0 for ipilimumab; p < 0.001 for each pembrolizumab arm versus ipilimumab). Fewer patients treated with pembrolizumab experienced deterioration in GHS at week 12 (31% for pembrolizumab Q2W; 29% for Q3W and 44% for ipilimumab), with similar trends observed for individual functioning and symptoms scales. HRQoL was better maintained with pembrolizumab than with ipilimumab in patients with ipilimumab-naive advanced melanoma. CLINICALTRIALS. NCT01866319. Copyright © 2017 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Find related publications in this database (using NLM MeSH Indexing)
Antibodies, Monoclonal, Humanized - adverse effects
Antibodies, Monoclonal, Humanized - therapeutic use
Antineoplastic Agents, Immunological - adverse effects
Antineoplastic Agents, Immunological - therapeutic use
Female -
Health Status -
Humans -
Ipilimumab - adverse effects
Ipilimumab - therapeutic use
Male -
Melanoma - drug therapy
Melanoma - pathology
Middle Aged -
Patient Reported Outcome Measures -
Quality of Life -
Skin Neoplasms - drug therapy
Skin Neoplasms - pathology
Time Factors -
Treatment Outcome -

Find related publications in this database (Keywords)
Pembrolizumab
Patient-reported outcomes
Health-related quality of life
KEYNOTE-006
Advanced melanoma
EORTC QLQ-C30
© Meduni Graz Impressum